港股生物醫藥股拉昇 君實生物(1877.HK)領漲
格隆匯9月16日丨港股生物醫藥股盤中出現直線拉昇走勢,其中,君實生物(1877.HK)漲超6%領漲,基石藥業、維亞生物、康方生物均出現明顯拉昇。此前港股生物醫藥股持續回落,部分個股回調幅度一度超過30%,最近幾日出現逐步反彈走勢。機構普遍認為,生物醫藥股由於年初至今升幅太大,估值高的股份受市場情緒疲軟拖累,以及大部分公司中期業績均低於市場預期而出現持續回調,但相信最差情況已反映在上半年業績,下半年表現將隨着分銷渠道補貨而有所改善,加上秋冬季節衞生事件有可能出現反彈,可再次關注該板塊。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.